Glaxo's ViiV starts phase III studies for HIV-1
18th Nov 2016 14:46
(ShareCast News) - Specialist HIV company ViiV Healthcare, which is majority-owned by GlaxoSmithKline with Pfizer and Shionogi Limited as shareholders, has started two phase III studies to evaluate an investigational long-acting, injectable regimen of cabotegravir and rilpivirine for the treatment o
Read moreThursday broker round-up
27th Oct 2016 12:29
(ShareCast News) - Debenhams: JP Morgan keeps at underweight with a target price of 54p. AA: Berenberg stays at buy, 315p target. National Express: RBC reiterates outperform with a 405p target. LLoyds: UBS reiterates buy with a 67p target. GlaxoSmithKline: Credit Suisse reiterates neutral with a
Read moreGlaxo Q3 profit and revenue rise, boosted by weak pound
26th Oct 2016 12:24
(ShareCast News) - Drug maker GlaxoSmithKline - which generates much of its revenue outside the UK - reported a jump in third-quarter profit on Wednesday as it benefited from the weakening of the pound following the UK's decision to leave the European Union in June. In the three months to the end of
Read moreGSK submits shingles vaccine for US regulatory approval
24th Oct 2016 07:07
(ShareCast News) - Pharmaceutical behemoth GlaxoSmithKline announced it has submitted a shingles vaccine for a US regulatory approval. Shingrix, a non-live recombinant vaccine, which prevents herpes zoster, or shingles, in people aged 50 years or over, was submitted to the US Food and Drug Admini
Read moreSector movers: Tesco leads cyclicals higher, pharma drags
14th Oct 2016 12:54
(ShareCast News) - Cyclicals took over from defensives, with Tesco spearheading gains among food and drug retailers while pharma stocks acted as the main drag. Tesco shares accounted for the lion's share of the gains in that sector after Unilever said issues surrounding the supply of its leading bra
Read moreGlaxoSmithKline raises £477m from offloading final Aspen shares
29th Sep 2016 07:54
(ShareCast News) - GlaxoSmithKline has sold its remaining shares in South Africa's Aspen Pharmacare to raise 8.47bn rand (£477m). The FTSE 100 drugs and consumer healthcare group agreed to sell its final holding of 28.2m ordinary shares at a price of 300 South African rand per share and so no longer
Read moreGlaxo files US regulatory submission for sirukumab
23rd Sep 2016 13:59
(ShareCast News) - GlaxoSmithKline has filed a regulatory submission to the US Food and Drug Administration for the use of sirukumab for the treatment of rheumatoid arthritis. More specifically, it is for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) wh
Read moreGSK promotes consumer chief Emma Walmsley to CEO designate
20th Sep 2016 07:05
(ShareCast News) - Pharmaceutical giant GlaxoSmithKline announced on Tuesday that Emma Walmsley - the current chief executive of the company's consumer healthcare division - is to be appointed chief executive designate, and will succeed Andrew Witty as CEO when he retires next March. The FTSE 100 fi
Read moreGlaxoSmithKline's shingles vaccine proves highly effective
15th Sep 2016 07:40
(ShareCast News) - After its Shingrix shingles vaccine proved extremely successful in a trial among elderly patients, GlaxoSmithKline has begun planning regulatory applications for later this year. In a Phase III study on adults 70 years' old or above, two doses of Shingrix showed 90% efficiency com
Read moreTuesday broker round-up
13th Sep 2016 11:56
(ShareCast News) - GVC Holdings: Berenberg reiterates buy with a target price of 760p. Softcat: Citigroup reiterates buy, 410p target. GlaxoSmithKline: Jefferies downgrades to underperform with a 2300p target. Relx: UBS stays at buy with a 1600p target. GB Group: Citigroup starts coverage at buy
Read moreGSK submits European application for potential arthritis blockbuster
12th Sep 2016 12:43
(ShareCast News) - GlaxoSmithKline has applied to the European drug regulator to approve its rheumatoid arthritis treatment, sirukumab, which some analysts predict could generate at least £1bn a year within five years. GSK confirmed on Monday that it applied to the European Medicines Agency for appr
Read moreMonday broker round-up
12th Sep 2016 09:24
(ShareCast News) - Autotrader: Barclays reiterates equal-weight with a target price of 375p. Hikma: Jefferies maintains buy with a 2500p target. Wood Group: Exane BNP Paribas upgrades to buy with a 815p target. Man Group: Citigroup upgrades to buy with a 137p target. McCarthy & Stone: Goldman Sac
Read moreGlaxoSmithKline's Relvar Ellipta shows 'significant' test score for COPD
5th Sep 2016 07:08
(ShareCast News) - Tests of a GlaxoSmithKline respiratory drug have found a statistically significant reduction in the rate of attacks suffered by chronic obstructive pulmonary disease (COPD) patients compared to when they receive the standard treatment. The pioneering Salford Lung Study by GSK and
Read moreFriday broker round-up
2nd Sep 2016 19:04
(ShareCast News) - Pearson: JP Morgan reiterates neutral with a target price of 940p. Vodafone: UBS maintains buy with a 310p target. Glaxosmithkline: UBS keeps at neutral with a 1650p target. GKN: Canaccord reiterates buy with a 370p target. Legal & General: Macquarie keeps at neutral with a tar
Read moreSector movers: Vodafone weighs on mobile telecoms
1st Sep 2016 21:10
(ShareCast News) - News that CK Hutchison Holdings and VimpelCom had won European Union approval to merge, in the process creating Italy´s biggest wireless telecommunications provider, sent stock in Vodafone sharply lower and its sector gauge with it. Vodafone´s own unit in that Mediterranean countr
Read more